Last mentioned: Mar 17, 2026
Implementation
New list prices and Medicare negotiated rates take effect for Ozempic and Wegovy.
Price Cut Effective
Novo Nordisk's 50% list price reduction for Ozempic and Wegovy takes effect.
Regulatory Review
Australian health authorities expected to review mandatory labeling proposals.
Negotiated Prices Effective
New Medicare-negotiated prices for selected drugs are scheduled to take effect.
CEO Policy Call
Lars Fruergaard Jørgensen publicly urges Australia to mandate unhealthy food labels.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reductions for semaglutide products.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reduction for 2027.
Negotiation Deadline
Expected announcement of final negotiated prices for the first round of Medicare drugs.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on drug pricing.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies on high U.S. drug prices.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on high U.S. prices.
Supply Constraints Ease
Novo Nordisk increases production to meet surging Australian demand.
Medicare Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
CMS Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Wegovy Approved
TGA approves Wegovy for chronic weight management in Australia.
IRA Signed
Inflation Reduction Act grants CMS authority to negotiate drug prices.
Novo Nordisk is positioning its next-generation GLP-1 combination therapy, CagriSema, as a critical catalyst to maintain market dominance against Eli Lilly. The drug's potential for superior weight loss and improved metabolic outcomes offers a significant valuation tailwind for investors.
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, has called on the Australian government to implement mandatory labeling for unhealthy foods. He argues that while GLP-1 medications like Wegovy are transformative, they must be paired with systemic changes to the food environment to combat the obesity epidemic effectively.
Novo Nordisk has announced a significant reduction in the list prices for its leading GLP-1 medications, Ozempic and Wegovy, with cuts reaching up to 50%. This strategic move follows months of regulatory scrutiny and public pressure regarding the affordability of metabolic health treatments in the United States.
Novo Nordisk has announced a landmark decision to reduce the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50%. The move follows intense regulatory scrutiny and the implementation of Medicare price negotiations under the Inflation Reduction Act.
Novo Nordisk has announced a significant reduction in the list prices for its blockbuster GLP-1 drugs, Ozempic and Wegovy, effective in 2027. The move, which could see prices drop by up to 50%, comes amid intense political pressure and federal negotiations aimed at lowering healthcare costs for American consumers.
Novo Nordisk has confirmed it will reduce the list prices of its flagship GLP-1 therapies, Ozempic and Wegovy, by as much as 50% beginning in 2027. The move is a direct consequence of federal price negotiations and signals a major shift in the commercial strategy for the high-growth metabolic health market.
Novo Nordisk has announced a major strategic shift by pledging to reduce the list prices of its blockbuster GLP-1 drugs, Ozempic and Wegovy, by up to 50% starting in 2027. This move follows intense regulatory pressure and the inclusion of Ozempic in Medicare's price negotiation program.